Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accelerated Access Review

- PMLiVE

Pharma’s four options for innovation

Only genuinely creative companies will profit from the future

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

National Institute for Health and Care Excellence NICE logo

Janssen launches diabetes drug Invokana in UK

Launch coincides with draft NICE recommendation for the SGLT2 inhibitor

Biogen Idec building

NICE turns down Biogen Idec’s oral MS drug

UK HTA body says Tecfidera is not a cost-effective use of NHS resources

National Institute for Health and Care Excellence NICE logo

NICE calls for greater statin prescribing in wake of Lipitor generics

Wants more use of the drugs to help prevent cardiovascular disease

National Institute for Health and Care Excellence NICE logo

NICE reviews lung cancer drug guidance

Consults on availability of Roche's Tarceva and AZ's Iressa on NHS

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

- PMLiVE

NICE set to extend MabThera recommendation

Says Roche’s drug can be used on NHS to treat two serious forms of vasculitis

- PMLiVE

NICE recommends Sanofi’s oral MS drug

Aubagio backed for NHS use in England and Wales

- PMLiVE

J&J adds Israel to list of bioincubators

Expands pharma company’s global collaboration efforts

A drug bottle with a 'like' option on the label

05 Social Media: A Health Hazard?

The case to embrace going social

Havas Lynx

Creating a Lifeline to the New Digital User

Today, we’re focussed on getting to know our new target: she’s online, mobile, and connected to a large network of friends, information, and marketers who help her make decisions about...

Havas Lynx

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links